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(57) 	 ABSTRACT 
A delivery device includes a hollow container, and a plurality 
of biodegradable and/or erodible polymeric layers estab-
lished in the container. A layer including a predetermined 
substance is established between each of the plurality of 
polymeric layers, whereby degradation of the polymeric layer 
and release of the predetermined substance occur intermit-
tently. Methods for forming the device are also disclosed 
herein. 
15 Claims, 6 Drawing Sheets 
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DELIVERY DEVICE AND METHOD FOR 	 SUMMARY 
FORMING THE SAME 
A delivery device includes a hollow container, and a plu- 
CROSS-REFERENCE TO RELATED 	 rality of biodegradable and/or erodible polymeric layers 
APPLICATIONS 	 5 established in the container. A layer including a predeter- 
mined substance is established between each of the plurality 
This application claims the benefit of U.S. Provisional 	 of polymeric layers, whereby degradation of the polymeric 
Patent Application Ser. No. 60/911,606 filed Apr. 13, 2007, 	 layers andrelease ofthepredetermined substance occurinter- 
which is incorporated herein by reference in its entirety. 	 mittently. A method for forming the device is also disclosed 
10 herein. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made in the course of research partially 
15 
supported by a grant from the National Aeronautics and  
Space Administration (NASA) Bioscience and Engineering 
Institute, Grant No. NNC04AA21A, and from the National 
Institutes of Health (NIH) and the National Institute of Dental 
and Craniofacial Research (NIDCR), Grant No. DE015384. 20 
The U.S. government has certain rights in the invention. 
BACKGROUND 
The present disclosure relates generally to delivery devices 25 
and a method for forming the same. 
Parathyroid hormone (PTH) is a peptide hormone that is 
capable of exhibiting either anabolic or catabolic effects on 
bone, depending, at least in part, on the dosage and delivery 
pattern. Generally, a continuous high dose delivery of PTH 30 
leads to catabolic effects, while a continuous low dose or a 
pulsatile high dose delivery of PTH results in anabolic effects 
on bone. Daily injections may be an anabolic treatment, how-
ever, such treatment is less convenient and may not be favor-
able to patients. As such, controlled delivery of PTH, and 35 
other like substances, in an anabolic fashion is highly desir-
able. 
Attempts have been made to devise a successful system for 
pulsatile substance release. Such systems may be classified as 
stimulus-induced pulsatile release systems or self-regulated 40 
pulsatile release systems. In stimulus-induced delivery sys-
tems, drugs are triggered to release by external stimuli, such 
as temperature, pH, light, enzymes, electric and magnetic 
fields, and/or combinations thereof. While these stimulus-
responsive devices have shown promising pulsatile release 45 
characteristics, many of the stimuli are not suitable or pref-
erable for use in patients. In addition, most of the systems in 
this category are constructed using non-biodegradable poly-
mers. 
In self-regulated pulsatile release systems, drugs are usu- 50 
ally encapsulated within a barrier material, which is often 
composed of an erodible or biodegradable polymer. After the 
barrier material is dissolved, eroded or degraded, the drugs 
are rapidly released from the inner reservoir core. These 
systems are usually biocompatible and biodegradable, but 55 
multiple barriers or coatings may be required to achieve the 
desired multiple pulses of release. Multiple layers may, how-
ever, pose challenges in material properties and device fabri-
cation technologies, often resulting in inconsistency. 
Other attempts to devise a successful system for pulsatile 60 
substance release have included combining the self-regulated 
release reservoir design with a microfabrication technique. 
Disk-shaped biodegradable polymeric chips have been fabri-
cated to achieve multi-pulse drug release. While this device 
may be useful, the reservoirs in the device are arranged par- 65 
allel to each other, which potentially wastes space and limits 
the miniaturization capacity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Features and advantages of embodiments of the present 
disclosure will become apparent by reference to the following 
detailed description and drawings, in which like reference 
numerals correspond to the same or similar, though perhaps 
not identical, components. For the sake of brevity, reference 
numerals having a previously described function may or may 
not be described in connection with subsequent drawings in 
which they appear. 
FIGS. lA through IF depict a primarily perspective sche-
matic illustration of an embodiment of a fabrication process 
of an implantable pulsatile delivery system, where FIG. lE is 
shown as a cross section of FIG. IF taken along the 1E-1E 
line; 
FIG. 2 is a schematic and cross-sectional flow diagram 
depicting another embodiment of a fabrication process of an 
implantable pulsatile delivery system; 
FIGS. 3A through 3C depict scanning electron microscope 
(SEM) micrographs of polyanhydride specimens (including 
polyethylene glycol (PEG), sebacic acid (SA), and 1,3-bis 
(carboxyphenoxy)propane (CPP)) with different composi-
tions after erosion in 0.1 M PBS at 37° C. for 24 h, where FIG. 
3A includes PEG/SA/CPP -0/20/80, FIG. 3B includes PEG/ 
SA/CPP=2.5/20/80, and FIG. 3C includes PEG/SA/CPP/ 
=7.5/20/80; 
FIG. 4 is a graph depicting a pulsed release profile of 
bovine serum albumin (BSA) from an embodiment of the 
delivery device including four layers of BSA, and polyanhy-
dride layers (with PEG amount of 1.6% in the polyanhydride 
copolymer) having a thickness of about 230±20 µm (n -3); 
FIG. 5 is a graph depicting the release accumulation of 
BSA from embodiments of the delivery device having four 
layers of BSA, and isolation layers with different thicknesses; 
FIG. 6 is a graph depicting the cumulative release of BSA 
from embodiments of the delivery devices having three layers 
of BSA, and different compositions of polyanhydrides as 
isolation layer materials; 
FIG. 7 is a graph depicting the pulsed release profiles of 
parathyroid hormone (PTH) and BSA from embodiments of 
the delivery device, each device including first and second 
substance layers loaded with PTH, third and fourth substance 
layers loaded with BSA, and polyanhydride isolation layers 
(with PEG amount of 1.6% in the polyanhydride copolymer) 
with a thickness of 230 µm; 
FIG. 8A is a graph depicting the PTH concentration in 
device eluent measured using a PTH (1-34) ELISA kit with 
PTH antibody coated wells, where the devices included four 
layers of PTH and were incubated in PBS at 37C., the eluent 
was collected at 24 h, 48 h, 72 h, and 96 h, respectively, and 
where the concentration of PTH in the eluent of the control 
devices (no PTH loaded) was less than 1 pg/µl; and 
FIG. 8B is a graph depicting the biological activity (values 
are the mean for triplicate samples) of eluent from devices as 
described in FIG. 8A, the PTH receptor-mediated adenylate 
cyclase was stimulated by treating ROS (17/2.8) cells with 
US 8,623,397 B2 
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known concentrations of PTH (1-34) or with devices eluent 	 After the mold 30 is printed, a solvent (e.g., ethanol) may 
(from control layers or PTH layers) of different layers, the 	 be used to dissolve the intermediate layer 16 (shown in FIG. 
cAMP in the cells was extracted and a cAMP binding protein 	 113). It is to be understood that the solvent is selected such that 
assay was performed to determine cAMP levels, and the level 
	 it dissolves the intermediate layer 16, but does not dissolve 
of cAMP in all the control devices (no PTH loaded) was less 5 layers 12, 14. As such, the solvent selected will depend, at 
than 2 pg/ld. 	 least in part, on the material used for the intermediate layer 16 
and the materials used for the layers 12, 14. Furthermore, the 
DETAILED DESCRIPTION 	 materials used for layers 12, 14 may be different from that 
used for layer 16 so that selective dissolution of layer 16 is 
Embodiments of the delivery device disclosed herein io achievable. As shown in FIG. 1C, the space from which the 
include a biodegradable polymer system with tunable erosion 	 intermediate layer 16 is removed may be filled with a solution 
properties to enable controlled pulsatile release of one or 	 of a material 18 that will form the container 20. The material 
more substances. The intervals between the pulses may be the 	 18 may be any material that maintains its structural integrity 
same or different, and may advantageously be tailored for 	 prior to completion of substance release from the device 10. 
specific needs. Furthermore, the device may be configured in 15 In an embodiment, the material 18 is poly(L-lactide) (PLLA). 
a variety of different ways, for example, to release the same 	 Non-limitative examples of other suitable materials 18 
substance over different pulses, to release a different sub- 	 include polymeric materials selected from natural or syn- 
stance or multiple substances at each pulse, to release the 	 thetic polymers, degradable polymers, non-degradable poly- 
same or different amounts of the substance at least pulse, or 	 mers, or partially degradable polymers, proteins, polysaccha- 
combinations thereof. 	 2o rides, hydrocarbon polymers, artificial proteins, and 
Such devices may be suitable for systemic and for local 	 combinations thereof. More specific non-limitative examples 
therapies. The device disclosed herein is biocompatible, and 
	
include poly(lactide-co-glycolide) (PLGA), polyglycolic 
may be implanted in humans and animals to deliver therapeu- 	 acid (PGA), polyanhydrides, poly(ortho ethers), polycapro- 
tics or other agents. As non-limiting examples, the device 	 lactone, poly(hydroxy butyrate), poly(phosphoesters), poly 
disclosed herein may be configured for osteoporosis treat-  25 (propylene fumarate), polyphosphazenes, polycarbonates, 
ment, bone regeneration, defective tissue treatment, ovula- 	 polyethylene, polyurethane, copolymers thereof, and/or com- 
tion induction, treatment of vasomotor symptoms, treatment 	 binations thereof. PLLA may be particularly suitable because 
of urogenital symptoms, endometrial hyperplasia treatment, 	 of its biocompatibility and biodegradability, as well as its 
allergic rash treatment, eczema treatment, and/or the like, 	 good mechanical properties. Such a material may be advan- 
and/or combinations thereof. 	 30 tageous in that there is no need for retrieval of empty devices 
Referring now to FIGS. 1A through 1F, an embodiment of 
	
10 after the completion of substance release. 
the method for forming an embodiment of the device 10 (see 	 This material solution 18 may be cast into the mold 30, 
FIG. 1E (a cross-sectional view) and FIG. 1F (a perspective 	 whereby the material solution 18 takes the shape of the origi- 
view) is shown. Very generally, the method includes provid- 	 nal intermediate layer 16. The material solution 18 is allowed 
ing a hollow container 20 (FIG. 1D), and establishing alter-  35 to dry. 
nating layers of a biodegradable and/or erodible polymer 22 
	
As shown in FIG. 1D, the remaining mold 3 0 (interior layer 
and a predetermined substance 24 in the hollow container 20. 	 12, exterior layer 14, and bottom 26) is removed, leaving 
In an embodiment, each of the alternating polymeric layers is 	 hollow container 20. The process by which the mold 30 is 
a surface-erosion polymer. 	 removed, depends, at least in part, on the material used to 
FIGS. 1A through 1D together depict the formation of the 40 form the mold 30. In an embodiment, the mold 30 is removed 
hollow container 20. In an embodiment, the hollow container 	 by dissolution. The container 20 may be washed, dried, and 
20 is formed using a reverse solid free form fabrication tech- 	 stored, as desired. 
nique. As shown in FIG. 1A, a mold 30 having a desired shape 	 FIG. 1E depicts the incorporation of the layers 22, 24 into 
for the hollow container 20 is formed having a bottom 26, an 	 the container 20. Prior to such incorporation, the layers 22, 24 
interior layer 12, an exterior layer 14 and an intermediate 45 are formed. The polymer layer 22 (also referred to herein as 
layer 16 between the layers 12, 14. The configuration of the 	 isolation layer 22) may be a copolymer of a sebacic acid 
mold 30 (and the formed container 20) may have any desir- 	 anhydride precursor, a 1,3-bis(carboxyphenoxy) propane 
able size and/or shape. In an embodiment, the mold 30 and 	 anhydride precursor, and a poly(ethylene glycol) anhydride 
container 20 are substantially cylindrical. Generally, the 	 precursor. Non-limiting examples of these copolymers and 
thickness of the intermediate layer 18 is equal to the distance 50 methods of forming the same are discussed in U.S. Provi- 
of the space between the layers 12, 14 of the mold 30. 	 sional Patent Application No. 60/794,617, filed on Apr. 25, 
In an embodiment, the design of the mold 30 is created and 
	
2006, incorporated by reference herein. The PEG segments 
converted into a stereolithography (STL) file using, for 	 are incorporated into polyanhydride copolymers, at least in 
example, Rhinoceros software (Robert McNeel & Associ- 	 part, to modulate the erosion rate and to improve processing 
ates, Seattle, Wash.), and then imported into, for example, 55 properties of the polyanhydride films/layers 22. With increas- 
Modelworks software (Solidscape) to convert the file for 	 ing PEG content, the polyanhydride erosion rate increases. 
three-dimensional (3D) printing. The mold 30 may be printed 	 Without being bound to any theory, it is believed that the 
from two nozzles in a layer-by-layer fashion using a rapid 	 structural tunability of such polyanhydrides will advanta- 
prototyping machine (Modelmaker II, Solidscape). In a non- 	 geously enable a broad range of lag times (between substance 
limiting example, different colored waxes may be used to 6o release) and various device 10 sizes. 
form the layers 12, 14 and the intermediate layer 16. This 	 Other non-limiting examples of suitable isolation layers 22 
enables one to easily distinguish the multiple layers 12,14,16 
	
include polymeric materials selected from natural or syn- 
of the mold 30. 	 thetic degradable polymers, proteins, polysaccharides, 
The computer-assisted design (CAD) andreverse solid free 	 hydrocarbon polymers, artificial proteins, and/or combina- 
form fabrication technique may advantageously aid the accu-  65 tions thereof. Specific non-limiting examples include poly 
rate fabrication of devices 10 having various shapes and sizes, 	 (lactide-co-glycolide) (PLGA), polyglycolic acid (PGA), 
thereby ensuring repeatability of the manufacturing process. 	 poly(L-lactic acid) (PLLA), polyanhydrides, poly(ortho 
US 8,623,397 B2 
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ethers), polycaprolactone, poly(hydroxy butyrate), poly 
(phosphoesters), poly(propylene fumarate), polyphosp-
hazenes, polycarbonates, polyurethane, copolymers thereof, 
and/or combinations thereof. 
To form the layer 22, the selected polymer(s) is/are heated 
until melted. The polymeric melt is then cooled down (e.g., to 
room temperature) and compressed into films of a desirable 
thickness. It is to be understood that the composition and/or 
thickness selected for the layer 22 depends, at least in part, on 
the desirable release characteristics (lag time and release 
pattern) for the device 10. Upon formation, the layer 22 may 
be divided into any desirable shape for incorporation into the 
container 20. 
The layer 24 including the predetermined substance may 
be formed by mixing the predetermined substance with a film 
forming material to form a solution, and casting the solution 
onto a removable substrate. Non-limiting examples of the 
film forming material include polymeric materials selected 
from natural or synthetic hydrophilic polymers, natural or 
synthetic amphophilic polymers, proteins, polysaccharides, 
hydrocarbon polymers, lipids, artificial proteins, and/or com-
binations thereof. More specific non-limitative examples 
include alginate, PEG, collagen, gelatin, hyaluronic acid, 
starch, glycogen, cellulose, caragena, dextran, chitin, chito-
san, pectin, heparan, heparan sulfate, copolymers thereof, 
small water soluble molecules (such as sugars, salts), and 
combinations thereof. It is believed that alginate may be 
particularly suitable as a carrier for the selected substance, in 
part, because of its biocompatibility and suitable processing 
properties. 
The solution is dried to form the substance layer 24, which 
may be removed from the substrate and divided into any 
desirable shape for incorporation into the container 20. N 
Non-limiting examples of suitable substances that are 
incorporated into layer 24 include drugs, vaccines, proteins, 
peptides, growth factors, hormones (e.g., PTH, luteinizing 
hormone release hormone (LHRH), 17(3-estradiol, estriol, 
progesterone, testosterone, cortisol, etc.), DNAs, RNAs, 
other biological molecules, non-biological molecules, and/or 
combinations thereof. The thickness and substance content of 
the layer 24 may be selected, at least in part, on the desirable 
amount of substance to be released and the release time. 
As shown in FIG. 1E, the layers 22, 24 are formed into 
disks having a shape configured to be introduced into the 
container 20. In an embodiment, each of the polymeric layers 
22 has an area that is equal to or larger than an area of each of 
the predetermined substance layers 24. 
The inner portion of the container 20 may be pre-wet with 
a desirable liquid (e.g., ethanol), and the layers 22, 24 are 
alternately introduced into the container 20. 
It is to be understood that the layers 24 including the 
predetermined substance may be the same or different 
throughout the device 10. For example, the substance loading 
may be higher in some layers 24 than in others 24, or the type 
of substance may be different in two or more layers 24. In a 
non-limiting example, the amount of substance loaded in 
each layer 24 is 50% higher than the substance loading in the 
layer 24 immediately above, inpart, to overcome the potential 
adsorption and diffusive losses of the released substance in 
lower layers 24. 
Once the layers 22, 24 are established in the container 20, 
the device 10 may be compressed under pressure for a pre-
determined time. Additional material (which may be the same 
as or different from the material 18 used to form the container 
20) may be added to the device 10 to fill any spaces between 
loaded layers 22, 24, and any gaps between the stacked layers 
6 
22, 24 and the container 20. In an embodiment, the additional 
material seals the layers 22, 24 in the device 10. 
The device 10 may be air purged for a predetermined time 
to accelerate solvent evaporation. The device 10 may also be 
5 dried for a predetermined time. 
FIG. 2 depicts another embodiment of the device 10 fab-
rication method. Generally, the method includes forming an 
assembly or stack 40 of the alternating layers 22, 24, as shown 
at reference numeral 200, and then establishing an outer layer 
10 42 on the assembly/stack 40 of layers 22, 24, as shown at 
reference numeral 202. The assembly 40 may be formed by 
stacking a desirable number of layer 22, 24 discs, which may 
be formed via the methods disclosed hereinabove. In another 
embodiment, the layers 22, 24 may be stacked, and then the 
15 stack 40 may be configured into a desirable shape. 
The outer layer 42 acts as a container 20 for the assembly/ 
stack 40 of layers 22, 24 (similar to FIG. 1E). The outer layer 
42 may be made up of material 18. In some instances, the 
outer layer 42 is coated over the stack 40, and in other 
20 instances, the outer layer 42 is a pre-formed hollow container 
(such as container 20, described hereinabove) that receives 
the assembly/stack 40. 
When the outer layer 42 is coated on the stack 40, any 
suitable deposition process may be used, including, but not 
25 limited to dip coating, spaying, or wrapping with a pre-fab-
ricated film or sheet. It is to be understood that such coating 
processes enable the material of the outer layer 42 to conform 
to the layers 22, 24. The outer layer 42 may be deposited to 
completely encapsulate the assembly 40, or it may be depos- 
30 ited such that one of the layers 22, 24 in the assembly 40 
remains exposed (as shown in FIG. 2). The positioning and 
thickness of the outer layer 42 depends, at least in part, on the 
desirable release characteristics for the device 10. For 
example, if immediate release of the substance in layer 24 is 
35 desirable, outer layer 42 will not be deposited on the outer-
most layer 24 of the stack 40. 
When the pre-formed hollow container 20 is used as the 
outer layer 42, it is to be understood that the shape/configu-
ration of the container 20 is selected or configured such that 
40 the interior hollow portion is able to receive the stack 40. The 
stack 40 may also be configured during fabrication to fit into 
a desirable container 20. It is to be understood that an addi-
tional material (which may be the same as or different from 
the material 18 used to form the outer layer 42/container 20) 
45 may be added to the device 10 to fill any spaces between the 
layers 22, 24 of the stack 40, and any gaps between the stack 
40 and the outer layer 42. 
It is to be understood that either layer 22 or 24 may form the 
outermost layer, for example, as shown in FIG. lE (layer 22 is 
50 the outermost layer of the stack) or in FIG. 2 (layer 24 is the 
outermost layer of the stack). Yet further, it is to be understood 
that the outermost layer may be formed of a temporary pro-
tective layer configured to dissolve away after implantation. 
To further illustrate embodiment(s) of the present disclo- 
55 sure, an example is given herein. It is to be understood that 
this example is provided for illustrative purposes and is not to 
be construed as limiting the scope of the disclosed embodi-
ment(s). 
60 	 EXAMPLE 
Embodiments of the delivery device 10 disclosed herein 
were fabricated. Some of devices 10 included isolation layers 
22 of three-component polyanhydrides, and layers 24 with 
65 parathyroid hormone or bovine serum albumin as the prede- 
termined substance. The three component polyanhydride iso- 
lation layers 22 were composed of sebacic acid (SA), 1,3-bis 
US 8,623,397 B2 
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(p-carboxyphenoxy) propane (CPP), and poly(ethylene 	 30 seconds every fifteen minutes. At the end of the reaction, 
glycol) (PEG). These layers 22 were synthesized and charac- 	 the resulting polymer melt was stored in a vial filled with 
terized by NMR, GPC and FTIR. Lyophilized parathyroid 	 nitrogen at about —20° C. 
hormone, PTH(1-34), was obtained from Bachem Bioscience 	 The newly synthesized polyanhydride copolymers were 
Inc. (Torrance, Calif.), and bovine serum albumin (BSA, 5 then heated until melted. The polyanhydride melt was then 
Fraction V) was purchased from Sigma (St. Louis, Mo.). 	 cooled down to room temperature, and compressed into films 
Poly(L-lactic acid) (PLLA), with an inherent viscosity of 	 of various thickness with the pressure of 5x10' Pa for 5 min 
approximately 1.6, was purchased from Boehringer Ingel- 	 using Carver® Presses (Carver Inc., IN). The polyanhydride 
heim (Ingelheim, Germany) and was used to form the con- 	 films were then punched into disks with a diameter of 3.0 mm. 
tainer 20. Sodium alginate was obtained from Pronova io Substance Delivery Device Fabrication 
Biopolymer (Drammen, Norway), and dichloromethane and 	 The inner side of PLLA cylinder was first pre-wetted with 
1,4-dioxane were purchased from Aldrich Chemical Com- 	 ethanol. The PTH or BSA disks and polyanhydride disks 
pany (Milwaukee, Wis.). 	 were alternately introduced into the PLLA cylinder (see, for 
Scanning Electron Microscopy (SEM) Examination of Ero- 	 example, FIG. 1E). In those examples including the PTH 
sion 	 15 layer, the loaded amount of PTH in each layer was 50% 
Rod-shaped polyanhydride specimens (2 mm in diameter 	 higher than that in the layer immediately above. After the 
and 4 mm in length) with various chemical compositions 	 PTH or BSA and polyanhydride layers were loaded, the 
were placed in LoBind tubes (EppendorfAG, Germany) con- 	 device was compressed with a pressure of 5x10' Pa for about 
taining 1.0 ml of phosphate buffered saline (PBS, 0.1 M, pH 	 10 min. A PLLA solution (10% wt/v) was carefully added to 
7.4). The tubes were kept in an incubator at 37° C. for 24 h. 20 fill the spaces between loaded substance (PTH or BSA) layers 
The specimens were then removed and vacuum-dried for 24 	 and isolation layers (24 and 22, respectively, shown in FIG. 
h. The specimens were cross-sectioned, gold-coated and 
	
1E), and any gap between the stacked films and the PLLA 
examined with scanning electron microscopy (SEM, Philips 	 cylinder. The device was then air purged for about 30 min to 
XL30 EEG) at 10 W. 	 accelerate the solvent evaporation, and vacuum dried for 24 h. 
Device Frame Design and Fabrication 	 25 In vitro BSA/PTH Release 
A cylindrical mold (3.2 mm in inner diameter, and 3.7 mm 	 The substance-loaded devices were immersed in 2 ml PBS 
in outer diameter) with one end sealed was designed and 	 (0.1 M, pH=7.4) and incubated at 37° C. After designated 
converted into a stereolithography (STL) file using Rhinoc- 	 times, the medium was collected and replaced with equal 
eros software (Robert McNeel &Associates, Seattle, Wash.). 	 amount of fresh PBS. The collected medium was stored at 
The STL file was imported into Modelworks software (Sol-  3o about —20° C. until analysis. The concentration of PTH in the 
idscape) to convert the file for 3D printing. To build the mold, 	 released medium was measured using PTH (1-34) ELISA 
red wax and green wax were printed from two nozzles in a 	 assay (Immutopics Inc., San Clemente, Calif.). The amount 
layer-by-layer fashion using a rapid prototyping machine 	 of released BSA was measured using a MicroBCA protein 
(Modelmaker 11, Solidscape) (FIG. 1A). 	 assay (Pierce, Rockford, Ill.). 
After the cylindrical mold was printed, ethanol was used to 35 In vitro PTH (1-34) Bioactivity Assay 
dissolve the green wax of the mold (FIG. 113). A PLLA 	 The in vitro bioactivity of released PTH was determined by 
solution (10% wt/v) was cast into the mold (taking the shape 	 adenylate cyclase stimulation assay and cAMP binding pro- 
of the original green material), and was air dried for 3 days 	 tein assay. Briefly, rat osteosarcoma cells (ROS 17/2.8) were 
(FIG. 1C). The mold containing the polymer was washed in 	 treated with PTH (1-34) of known concentrations, or with 
37° C. cyclohexane to dissolve the red wax mold (FIG. 1D). 40 eluent from the PTH delivery device for designated times in 
The obtained PLLA cylinder was then washed with ethanol 	 calcium- and magnesium-free hanks' balanced salt solution 
and water, and subsequently air-dried. The PLLA cylinder 	 (Invitrogen, Carlsbad, Calif.) containing 0.1% BSA and 1 
was stored in a desiccator before use. 	 mM isobutylmethylxanthine (IBMX). After incubation of the 
Fabrication of PTH, BSA and Polyanhydride Films 	 treated cells at 37° C. for about 10 min, the cAMP in cells was 
PTH films: PTH (1-34) (0.3 mg) and alginate (250 mg) 45 extracted by adding cold perchloric acid. The cAMP extracts 
were mixed and dissolved in 8 ml Milli-Q water (18.2 	 were then neutralized by adding KOH solution, and were 
MQ-cm) at 4° C. The solution was cast on a hexagonal poly- 	 centrifuged to remove the precipitate. The [3H] -cAMP (ICN, 
styrene weigh boat (Fisher Scientific, USA), and vacuum 	 Irvine, Calif.) was incubated with standards or unknowns and 
dried at 4° C. for about 2 weeks. The thickness of the film was 	 cAMP binding protein for 90 min on ice. The unbound [3H]- 
about 100 µm. The desired thickness may be achieved by 50 cAMP was removed by adding dextran-coated charcoal. The 
controlling the amount of casting solution on the weigh boat. 	 samples were then centrifuged and the supernatant of each 
PTH/alginate disks with a diameter of 2.0 mm were punched 	 tube was decanted to a scintillation tube. The radioactivity of 
out from the PTH/alginate films. 	 the supernatants was determined using a liquid scintillation 
BSA Films: The procedure used to prepare the PTH/algi- 	 counter (Wallacs 1410; Wallac, Gaithersburg, Md.) and 
nate films was also used to prepare the BSA/alginate thin 55 cAMP levels were calculated by the loglogit method using a 
disks. Briefly, a BSA/alginate solution was prepared by mix- 	 standard curve. 
ing BSA (0.15 g) and alginate (0.25 g) in Milli-Q water (10 	 Polyanhydrides Surface Erosion 
ml). The BSA/alginate solution was then cast into thin films 	 The three-component (SA, CPP and PEG) polyanhydrides 
and punched into BSA/alginate disks with a diameter of 2.0 	 showed surface erosion characteristics (see FIG. 3 series). 
mm. 	 60 Polyanhydrides containing PEG segments (FIGS. 3B and 3C) 
Polyanhydride films: SA, CCP and PEG anhydride precur- 	 exhibited faster erosion rates compared to those without PEG 
sors were charged into a pre-dried tube. Alternating cycles of 
	 (FIG. 3A). The erosion depth of the cylindrical polyanhydride 
vacuum and nitrogen purging were repeated three times, and 	 without PEG segments (FIG. 3A) was about 100 µm after 24 
the vacuum was maintained inside the tube at the end. The 	 h in PBS at 37° C., while the erosion depths were about 380 
tube was then immersed into an oil bath and the vacuum was 65 µm and 650 µm for polyanhydrides with 2.5% and 7.5% PEG 
maintained under continuous pumping. The reaction mixture 	 (FIGS. 3B and 3C, respectively) in the copolymers, respec- 
was stirred vigorously and purged with dry nitrogen for about 	 tively. There were evident intervening spaces between the 
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eroded and un-eroded portions of all surface-eroded samples. 	 conditions. The catabolic or anabolic action of PTH (and 
For polyanhydride with 2.5% PEG (FIG. 313), a small portion 	 potentially other like therapeutic agents) depends on the pat- 
of the particles from the eroded polyanhydride was found to 	 tern of delivery: continuous exposure to PTH results in bone 
be separated from the bulk of polyanhydride. As PEG content 	 resorption, whereas intermittent administration (pulsatile 
of the copolymer increased to 7.5% (FIG. 3C), virtually the 5 release) of PTH increases bone formation. Therefore, the 
entire eroded portion was detached from the un-eroded por- 	 device 10 disclosed herein may be particularly suitable 
tion of the cylindrical polyanhydride. The eroded surfaces 	 because the release of the substance may be controlled and 
were floppy and porous. The surface roughness increased 	 relatively precisely modulated. 
with increasing PEG content of the polyanhydride. 	 The biocompatible materials used to form the device 10 
Pulsatile Protein Release from the Device 	 io render the device 10 suitable for implantation into a human or 
The release profile of the device including BSA layers was 	 other animal. Furthermore, the configuration and fabrication 
investigated. FIG. 4 shows four well-defined pulses with an 	 techniques used result in relatively small device 10 sizes, and 
interval of 24 h between two adjacent pulses. The released 	 the potential for further miniaturization using such tech- 
amount of BSA was almost the same for each pulse. As shown 	 niques also exists. 
in the graph, the released amounts of BSA between pulses 15 	 The device 10 disclosed herein also advantageously pre- 
were very low. 	 vents device leakage. If the isolation layer 22 or sealant filling 
It is believed that the time interval between two pulses (lag 	 has defective pores connecting or increasing diffusion 
time) is controllable by the thickness of polyanhydride films, 	 between substance layers 24, body fluid (water) is likely to 
which acted as isolation layers 22. One device including BSA 	 penetrate inside the substance layer 24 before the isolation 
layers had polyanhydride films with varying thicknesses (230 20 layer 22 is eroded. This may lead to unpredictable substance 
µm, 310 µm, and 400 µm, respectively). The lag time 	 release patterns. Embodiments of the device 10 aim to prevent 
increased approximately linearly with the thickness of the 	 such leakage. First, the size of substance layers 24 may be 
polyanhydride films (isolation layer 22). As shown in FIG. 5, 	 designed to be smaller than that of isolation layers 22 (see 
the lag time increased from about 24 h to about 40 h when the 	 FIG. 1E), such that the contact area between the substance 
thickness of the polyanhydride layer (with 1.6% PEG in the 25 layers 24 and isolation layers 22 near the outer edges (i.e., 
polyanhydride) increased from 230 µm to 400 µm. 	 areas of a higher defective probability) is decreased. Second, 
The lag time may also be controlled by polyanhydride 	 the sealant material is used to fill the gap between the layers 
composition (see FIG. 6). The results shown in FIG. 6 were 	 22, 24 and the container 20. Third, the device 10 may be 
for devices including three BSA layers with isolation layers 	 continually compressed with constant pressure during the 
of the same thickness, but different PEG content, therebe-  30 sealing process to reduce the possibility of air pocket forma-
tween. Three pulses of BSA release were observed on each 	 tion. 
cumulative release curve. The lag times of BSA release were 	 The delivery device 10 disclosed herein includes, but it not 
about 24 h and 32 h for the devices with PEG contents of 1.1 % 
	
limited to the following advantageous characteristics. All 
and 2.5%, respectively. As the PEG content was further 	 layers of materials (e.g., alginate, polyanhydride, PLLA) 
increased to 7.5% and 10.0%, the substance was released 35 used to form the device 10 are biocompatible and biodegrad- 
much faster and the lag times were about 14 h and 12 h, 	 able. As such, the device 10 may be implanted in vivo with 
respectively. At these two high PEG contents, the pulses 	 minimal immuno-reaction. Furthermore, devices 10 of vari- 
became less defined to nearly un-identifiable. BSA was 	 ous shapes and sizes may be accurately fabricated using the 
released almost at a constant rate when PEG content in the 	 reverse solid free form fabrication technique. Still further, 
polyanhydride was about 10.0%. 	 40 embodiments of the device 10 are able to deliver more than 
The release of different substances at different time points 	 one substance, and the substance loadings may be tailored 
was realized with one embodiment of the delivery device. In 	 over a broad range. 
FIG. 7, both PTH and BSA were loaded in the same device 	 While several embodiments have been described in detail, 
(the first two layers were loaded with PTH, and the third and 	 it will be apparent to those skilled in the art that the disclosed 
fourth layers were loaded with BSA). Two pulses of PTH 45 embodiments may be modified. Therefore, the foregoing 
were first released between 0 and 50 h, followedby two pulses 	 description is to be considered exemplary rather than limit- 
of BSA released between 50 h and 100 h. The released pulses 	 ing. 
appeared at about every 24 h, as designed. 	 What is claimed is: 
In vitro PTH Release and Bioactivity 	 1. A delivery device, comprising: 
Multi-pulse release of PTH from the device was also exam-  50 	 a hollow container; 
ined. FIG. 8A illustrates the amount of PTH released from 	 a plurality of solid polymeric layers established in the 
each layer in the device (every pulse of release is associated 	 container, wherein the solid polymeric layers chosen 
with one PTH-containing layer). Similar amounts of PTH 	 from poly(lactide-co-glycolide) (PLLA); polyglycolic 
were released from each layer of the device. The bioactivity of 	 acid (PGA); poly(L-lactic acid) (PLLA); polyanhy- 
PTH released from each layer was measured in vitro (see FIG. 55 	 drides; poly(ortho ethers); polycaprolactone; poly(hy- 
813). Based on the standard curve of PTH (positive control), 	 droxy butyrate); poly(phosphoesters); polypropylene 
the bioactivity of PTH released from the last layer was 	 fumarate); polyphosphazenes; polycarbonates; polyure- 
equivalent to 47.5 pg/µl PTH. Compared to the released 	 thane; copolymers thereof; a copolymer of a sebacic 
amount of PTH from the last layer in FIG. 8A, it was calcu- 	 acid anhydride precursor, a 1,3-bis(carboxyphenoxy) 
lated that 90.9% PTH was bioactive after it was released from 60 	 propane anhydride precursor, and a poly(ethylene gly- 
the device. Similar results of released PTH from other layers 	 col) anhydride precursor; and combinations thereof; and 
were obtained. Therefore, it is believed that the released PTH 	 a solid layer including a film forming material and a pre- 
from the delivery system retained high bioactivity. 	 determined substance incorporated into the film forming 
PTH and other therapeutic agents are well known for their 	 material, the solid layer being established between each 
catabolic action resulting in bone resorption and an increase 65 	 of the plurality of solid polymeric layers, the film form- 
of calcium concentration in the blood. Interestingly, PTH also 	 ing material being chosen from alginate; polyethylene 
has anabolic action to stimulate bone formation under certain 	 glycol; collagen; gelatin; hyaluronic acid; starch; glyco- 
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gen; cellulose; caragena; dextran; chitin; chitosan; pec- 
tin; heparan; heparan sulfate; and combinations thereof; 
whereby degradation of the solid polymeric layers and 
release of the predetermined substance occur intermit-
tently 
wherein the surface area of the solid layer in contact with 
the solid polymeric layer is smaller than the surface area 
of the solid polymeric layer such that a gap exists 
between the plurality of solid polymeric layers at an 
outer edge of the solid layer; and the delivery device 
further includes a sealant material introduced into the 
gap. 
2. The delivery device as defined in claim 1 wherein the 
delivery device contains a plurality of solid layers including a 
predetermined substance, and wherein the predetermined 
substance for one of the plurality of solid layers is the same or 
different than the predetermined substance for an other of the 
plurality of solid layers. 
3. The delivery device as defined in claim 1 wherein the 
predetermined substance is selected from drugs, vaccines, 
proteins, peptides, growth factors, hormones, DNAs, RNAs, 
biological molecules, non-biological molecules, and combi-
nations thereof. 
4. The delivery device as defined in claim 1 wherein each of 
the solid polymeric layers is a surface-erosion polymer. 
5. The delivery device as defined in claim 1 wherein the 
delivery device contains a plurality of solid layers including a 
predetermined substance, and wherein an amount of the pre-
determined substance in one of the plurality of solid layers is 
higher than an amount of the predetermined substance in an 
other of the plurality of solid layers. 
6. The delivery device as defined in claim 1 wherein the 
predetermined substance includes at least two different sub-
stances. 
7. A method for forming a delivery device, comprising: 
providing a hollow container; and 
establishing, in the hollow container, alternating solid lay-
ers of i) polymer and ii) a film forming material and a 
predetermined substance incorporated into the film 
forming material, wherein the polymer is chosen from 
poly(lactide-co-glycolide) (PLGA); polyglycolic acid 
(PGA); poly(L-lactic acid) (PLLA); polyanhydrides; 
poly(ortho ethers); polycaprolactone; poly(hydroxy 
butyrate); poly(phosphoesters); poly(propylene fuma-
rate); polyphosphazenes; polycarbonates; polyurethane; 
copolymers thereof; a copolymer of a sebacic acid anhy-
dride precursor, a 1,3-bis(carboxyphenoxy) propane 
anhydride precursor, and a poly(ethylene glycol) anhy-
dride precursor; and combinations thereof, and wherein 
the film forming material is chosen from alginate; poly-
ethylene glycol; collagen; gelatin; hyaluronic acid; 
starch; glycogen; cellulose; caragena; dextran; chitin; 
chitosan; pectin; heparan; heparan sulfate; and combi-
nations thereof, 
wherein the surface area of the solid layer in contact with 
the solid polymeric layer is smaller than the surface area 
of the solid polymeric layer such that a gap exists 
between the plurality of solid polymeric layers at an 
outer edge of the solid layer; and the delivery device 
further includes a sealant material introduced into the 
gap. 
8. The method as defined in claim 7 wherein providing the 
hollow container is accomplished by a reverse solid free form 
fabrication technique. 
9. The method as defined in claim 8 wherein providing the 
hollow container is accomplished by: 
12 
printing a mold of the hollow container, the mold having a 
bottom, an exterior layer, an interior layer, and a layer 
intermediate the exterior and interior layers; removing 
the intermediate layer; 
5 	 establishing a material that forms the hollow container 
between the interior and exterior layers and adjacent the 
bottom; and 
removing the interior layer, the exterior layer, and the bot- 
lo 
tom, thereby forming the hollow container of the mate-
rial. 
10. The method as defined in claim 7 wherein prior to 
establishing the alternating layers, the method further com-
prises forming the polymer layer by: 
15 	 melting the copolymer of the sebacic acid anhydride pre- 
cursor, the 1,3-bis(carboxyphenoxy) propane anhydride 
precursor, and the poly(ethylene glycol) anhydride pre-
cursor; and 
compressing the melted copolymer into a layer as it cools. 
20 11. The method as defined in claim 7, wherein prior to 
establishing alternating layers, the method further comprises 
forming the film forming material and predetermined sub-
stance layer by: 
mixing the predetermined substance with the film forming 
25 material, thereby forming a solution; and 
casting the solution onto a removable substrate. 
12. The method as defined in claim 7 wherein prior to 
establishing the alternating layers, the method further com-
prises pre-wetting an inner side of the hollow container with 
3o a liquid. 
13. The method as defined in claim 7, further comprising: 
compressing the delivery device with a predetermined 
pressure; 
adding a polymer to substantially fill any gaps within the 
35 	 hollow container; 
purging the delivery device; and 
drying the delivery device. 
14. An implantable delivery device, comprising: 
• hollow container selected from poly(lactide-co-gly- 
40 colide) (PLGA), polyglycolic acid (PGA), polyanhy-
drides, poly(ortho ethers), polycaprolactone, poly(hy-
droxy butyrate), poly(phosphoesters), polypropylene 
fumarate), polyphosphazenes, polycarbonates, polyeth-
ylene, polyurethane, copolymers thereof, or combina- 
45 	 tions thereof, 
• plurality of solid polymeric layers established in the 
container, wherein the solid polymeric layers is selected 
from poly(lactide-co-glycolide) (PLGA); polyglycolic 
acid (PGA); poly(L-lactic acid) (PLLA); polyanhy- 
50 drides; poly(ortho ethers); polycaprolactone; poly(hy-
droxy butyrate); poly(phosphoesters); poly(propylene 
fumarate); polyphosphazenes; polycarbonates; polyure-
thane; copolymers thereof; a copolymer of a sebacic 
acid anhydride precursor, a 1,3- bis(carboxyphenoxy) 
55 propane anhydride precursor, and a poly(ethylene gly-
col) anhydride precursor; and combinations thereof; and 
• solid layer including a film forming material and a pre-
determined substance incorporated into the film forming 
material, the solid layer being established between each 
60 of the plurality of solid polymeric layers, the film form-
ing material being chosen from alginate; polyethylene 
glycol; collagen; gelatin; hyaluronic acid; starch; glyco-
gen; cellulose; caragena; dextran; chitin; chitosan; pec-
tin; heparan; heparan sulfate; and combinations thereof, 
65 whereby degradation of the solid polymeric layers and 
release of the predetermined substance occur intermit-
tently 
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wherein the surface area of the solid layer in contact with 
the solid polymeric layer is smaller than the surface area 
of the solid polymeric layer such that a gap exists 
between the plurality of solid polymeric layers at an 
outer edge of the solid layer; and the delivery device 5 
further includes a sealant material introduced into the 
gap. 
15. The delivery device as defined in claim 1 wherein the 
film forming material is chosen from alginate; collagen; 
hyaluronic acid; glycogen; caragena; chitosan; pectin; hep- io 
arin; heparin sulfate; and a combination thereof. 
